Greatly Transformed Sinovac Set to Reawaken on Wall Street?

Maker of the CoronaVac vaccine for Covid-19 could soon resume trading on the Nasdaq after a nearly three-year pause, following two key legal developments Key takeaways: Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension Company’s revenue may have risen 80-fold or more since the suspension thanks to sales of its globally accepted CoronaVac Covid-19 vaccine By Doug Young By now, many people have heard of Sinovac Biotech Ltd. (SVA.US), the maker of one of…

Read More »